Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT07435038
PHASE1/PHASE2
Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Sponsor: Betta Pharmaceuticals Co., Ltd.
View on ClinicalTrials.gov
Summary
Evaluate the safety and tolerability of BPI-572270 in adult patients with specific RAS mutant advanced solid tumors.
Official title: A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
120
Start Date
2026-02-12
Completion Date
2029-10-28
Last Updated
2026-03-11
Healthy Volunteers
No
Conditions
Interventions
DRUG
BPI-572270
Oral Tablets